Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas

Area of Science:

• Oncology
• Pharmacology
• Cancer Research

Background:

• Systemic treatment for bone and soft tissue sarcomas saw limited progress until the 2000s.
• Rarity and heterogeneity of these cancers posed challenges for drug development.
• The 2010s marked a shift with the introduction and approval of novel molecularly targeted drugs.

Purpose of the Study:

• To review and summarize current molecularly targeted therapies approved for bone and soft tissue sarcomas.
• To discuss molecularly targeted therapies currently in development for these conditions.
• To highlight key advancements in systemic treatment for sarcomas.

Main Methods:

• Literature review of approved and investigational molecularly targeted therapies.
• Summary of drug approvals and their indications for bone and soft tissue sarcomas.
• Analysis of drug mechanisms, including tyrosine kinase inhibitors and monoclonal antibodies.

Main Results:

• Imatinib approval for gastrointestinal stromal tumors (GISTs) was a significant early success.
• Tyrosine kinase inhibitors (TKIs) like sunitinib and regorafenib are approved for GISTs.
• Pazopanib for non-GIST soft tissue sarcomas and denosumab for giant cell tumors of bone represent other key approvals.
• Olaratumab, a PDGFR-α inhibitor, demonstrated improved survival in soft tissue sarcoma patients.

Conclusions:

• Molecularly targeted therapies have significantly expanded systemic treatment options for sarcomas.
• Ongoing research and development continue to yield new therapeutic strategies.
• Targeted drug approvals offer improved outcomes for patients with bone and soft tissue sarcomas.